Menu
0

CDC/Complement-Modulated Antibody Expression Vectors

Fc-engineered human IgG1, human IgG2, and mouse IgG2a expression vectors designed to investigate complement enhancement or attenuation through Fc engineering.

CDC / COMPLEMENT MODULATED ANTIBODY EXPRESSION VECTOR SELECTION GUIDE

Compare seven Fc-engineered antibody expression vectors to select a suitable complement-modulated variant for your research.

Catalog No. Variant Engineering Mechanism Selection Guidance
AFV-22 Human IgG1 (HexaBody-Extended) E345K / E430G / E431K Extended Fc hexamerization engineering for investigating antigen-dependent complement activation.
AFV-21 Human IgG1 (HexaBody) E345K / E430G Fc hexamerization engineering for studying C1q recruitment and CDC.
AFV-25 Human IgG1 (SEHF) S267E / H268F CH2 engineering for evaluating C1q binding and complement-mediated activity.
AFV-20 Human IgG1 (WS) K326W / E333S CH2 engineering for studying complement-enhancing Fc interactions.
AFV-23 Human IgG1 (K322A) K322A C1q-contact-site engineering for complement-attenuation studies in human IgG1.
AFV-24 Human IgG2 (K322A) K322A Complement-attenuation studies using a human IgG2 Fc backbone.
AFV-10 Mouse IgG2a (Comp-Null) L235E / E318A / K320A / K322A Mouse IgG2a Fc engineering for investigating reduced complement and Fc-effector interactions.

Complement activity depends on antibody sequence, antigen density, Fc isotype, target cells, and assay conditions. Confirm C1q binding, complement deposition, and CDC experimentally.

Showing all 7 results